Pro&Pub
First Edition
Objective and purpose
The Projects and Publications (Pro&Pub) program was created by GLADEL to promote scientific research on lupus in Latin America, strengthen researchers' methodological skills, and facilitate the publication of local data in high-impact international indexed journals.
The initiative offers data from the GLADEL Original and GLADEL 2.0 cohorts and educational projects, methodological and statistical advice, personalized mentoring, and financial support, promoting the academic growth of the network and the development of projects with real impact on clinical practice.
Inicial stage
The initial call for proposals for the program received a great response within the GLADEL network:
- A total of 17 projects were received proposed by researchers from seven Latin American countries.
- Twelve projects were selected and supervised by the Pro&Pub Scientific Committee.
Impact and results
During the program's implementation, 12 active projects were completed, including one from the pediatric group, resulting in 13 manuscripts.
- Six manuscripts are currently in the process of being published, while the rest are still in development.
- The results were presented at national and international conferences, such as PANLAR, EULAR, ACR, and the World Lupus Congress.
- The research topics reflect the main issues in the region:
- Clinical characteristics of lupus in Latin America
- Comorbidities
- Pregnancy and lupus
- Treatments for lupus and their effectiveness
- Work productivity and quality of life
- Impact of lupus on pediatric caregivers
The program also strengthened the network of high-level scientific mentors, who provided methodological, statistical, and linguistic support, ensuring the quality of the work and compliance with international standards.
Projection for 2026
Following the success of its first edition, GLADEL plans to launch the second edition of the Pro&Pub program in 2026, expanding its scope and consolidating its role as a regional scientific training and research platform.
The challenge now is to sustain and expand this support model, generating new opportunities for more Latin American researchers to transform their ideas into published evidence and contribute to a deeper understanding of lupus in our region.
INDUSTRY PARTNERSHIPS.
In this new phase, GLADEL seeks to strengthen collaboration with the pharmaceutical industry and other strategic partners. Interested companies will be able to propose research topics aligned with scientific priorities and unmet needs in lupus, which will be evaluated by the Pro&Pub Scientific
Committee according to rigorous ethical and methodological criteria. Similarly, based on GLADEL's vast experience in clinical and epidemiological research, the network will also be able to suggest priority lines of work for the region to laboratories, in areas where there is a significant knowledge gap or where the generation of evidence could have an immediate clinical and health impact.
In this way, the program is consolidated as a space for responsible co-creation,
where questions relevant to both clinical practice and industry are transformed into high-impact published evidence.
First Edition
Objective and purpose
The Projects and Publications (Pro&Pub) program was created by GLADEL to promote scientific research on lupus in Latin America, strengthen researchers' methodological skills, and facilitate the publication of local data in high-impact international indexed journals.
The initiative offers data from the GLADEL Original and GLADEL 2.0 cohorts and educational projects, methodological and statistical advice, personalized mentoring, and financial support, promoting the academic growth of the network and the development of projects with real impact on clinical practice.
Inicial stage
The initial call for proposals for the program received a great response within the GLADEL network:
- A total of 17 projects were received proposed by researchers from seven Latin American countries.
- Twelve projects were selected and supervised by the Pro&Pub Scientific Committee.
Impact and results
During the program's implementation, 12 active projects were completed, including one from the pediatric group, resulting in 13 manuscripts.
- Six manuscripts are currently in the process of being published, while the rest are still in development.
- The results were presented at national and international conferences, such as PANLAR, EULAR, ACR, and the World Lupus Congress.
- The research topics reflect the main issues in the region:
- Clinical characteristics of lupus in Latin America
- Comorbidities
- Pregnancy and lupus
- Treatments for lupus and their effectiveness
- Work productivity and quality of life
- Impact of lupus on pediatric caregivers
The program also strengthened the network of high-level scientific mentors, who provided methodological, statistical, and linguistic support, ensuring the quality of the work and compliance with international standards.
Projection for 2026
Following the success of its first edition, GLADEL plans to launch the second edition of the Pro&Pub program in 2026, expanding its scope and consolidating its role as a regional scientific training and research platform.
The challenge now is to sustain and expand this support model, generating new opportunities for more Latin American researchers to transform their ideas into published evidence and contribute to a deeper understanding of lupus in our region.
INDUSTRY PARTNERSHIPS.
In this new phase, GLADEL seeks to strengthen collaboration with the pharmaceutical industry and other strategic partners. Interested companies will be able to propose research topics aligned with scientific priorities and unmet needs in lupus, which will be evaluated by the Pro&Pub Scientific
Committee according to rigorous ethical and methodological criteria. Similarly, based on GLADEL's vast experience in clinical and epidemiological research, the network will also be able to suggest priority lines of work for the region to laboratories, in areas where there is a significant knowledge gap or where the generation of evidence could have an immediate clinical and health impact.
In this way, the program is consolidated as a space for responsible co-creation,
where questions relevant to both clinical practice and industry are transformed into high-impact published evidence.